Last updated on
Cholesterol Conversations: Episode 1
ASCVD Management: Making the Case for Nonstatin Therapies
In this episode of Cholesterol Conversations, join Drs. Neha Pagidipati, Christie Ballantyne, and Gregory Piazza for a roundtable discussion that addresses recent guidance on ASCVD management, current gaps in ASCVD care, patient barriers to LDL-C lowering, and nonstatin therapies to consider for patients who don’t respond to statin therapy alone.
To listen to this episode, click the play button below or listen on Spotify or Apple Podcasts! Podcast coming soon to Google Podcasts.
HOST
Assistant Professor of Medicine, Division of Cardiology
Duke University School of Medicine
Member of the Duke Clinical Research Institute
Neha J. Pagidipati is an Assistant Professor of Medicine and cardiovascular disease prevention specialist. Since 2011, she has conducted research on cardiometabolic disease prevention, lifestyle modification, and weight management. Dr. Pagidipati is building the Duke Cardiometabolic Disease Prevention Program, which focuses on behavior change and risk factor management in patients with high risk of cardiovascular and metabolic diseases such as diabetes and obesity. She leads Duke University Health System projects to improve electronic health record systems and decision support tools. They include constructing an algorithm to predict short-term hospitalization among patients with diabetes; implementing a program to improve dyslipidemia among patients at high risk for cardiovascular disease (CVD); and analyzing obesity management using electronic health record data to improve care for patients with obesity and CVD risk.
GUEST SPEAKER
Chief, Section of Cardiovascular Research
Professor of Medicine
Baylor College of Medicine
Christie Ballantyne is an internationally renowned expert on lipids, atherosclerosis, and heart disease prevention. His many accomplishments have included being elected as Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. His research in biomarkers has led to the FDA approval of 2 biomarkers for risk prediction of CV and he has played a prominent role in the development and FDA approval of new therapies for treatment of lipids. With over 800 publications in the area of atherosclerosis, lipids, and inflammation, Christie also serves on the Editorial Board for Circulation and JACC.
GUEST SPEAKER
Director, Vascular Medicine Section, Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Gregory Piazza received his medical degree from the University of Massachusetts Medical School in Worcester, Massachusetts and completed his residency in internal medicine, chief medical residency, general cardiology fellowship, and advanced cardiovascular imaging fellowship at the Beth Israel Deaconess Medical Center in Boston. He also completed a National Heart, Lung, and Blood Institute-sponsored advanced fellowship in vascular medicine at Brigham and Women’s Hospital. Dr. Piazza’s research interests include the epidemiology, pathophysiology, diagnosis, treatment, and prevention of venous thromboembolism, thrombophilia-associated infertility, computerized decision support to improve cardiovascular outcomes, and stroke prevention in atrial fibrillation.
Listen to Episode 2:
